- Home
- TRSG vs BOLD Comparison
TRSG vs BOLD Comparison
Compare TRSG & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRSG
- BOLD
- Stock Information
- Founded
- TRSG 1996
- BOLD 2018
- Country
- TRSG Singapore
- BOLD United States
- Employees
- TRSG N/A
- BOLD N/A
- Industry
- TRSG
- BOLD
- Sector
- TRSG
- BOLD
- Exchange
- TRSG NYSE
- BOLD Nasdaq
- Market Cap
- TRSG 25.8M
- BOLD 30.3M
- IPO Year
- TRSG 2024
- BOLD 2024
- Fundamental
- Price
- TRSG $1.51
- BOLD $1.58
- Analyst Decision
- TRSG
- BOLD Buy
- Analyst Count
- TRSG 0
- BOLD 3
- Target Price
- TRSG N/A
- BOLD $22.50
- AVG Volume (30 Days)
- TRSG 46.6K
- BOLD 75.0K
- Earning Date
- TRSG 12-31-2024
- BOLD 05-12-2025
- Dividend Yield
- TRSG N/A
- BOLD N/A
- EPS Growth
- TRSG N/A
- BOLD N/A
- EPS
- TRSG N/A
- BOLD N/A
- Revenue
- TRSG $14,441,864.00
- BOLD N/A
- Revenue This Year
- TRSG N/A
- BOLD N/A
- Revenue Next Year
- TRSG N/A
- BOLD N/A
- P/E Ratio
- TRSG N/A
- BOLD N/A
- Revenue Growth
- TRSG 9.34
- BOLD N/A
- 52 Week Low
- TRSG $1.00
- BOLD $1.06
- 52 Week High
- TRSG $11.78
- BOLD $12.65
- Technical
- Relative Strength Index (RSI)
- TRSG N/A
- BOLD N/A
- Support Level
- TRSG N/A
- BOLD N/A
- Resistance Level
- TRSG N/A
- BOLD N/A
- Average True Range (ATR)
- TRSG 0.00
- BOLD 0.00
- MACD
- TRSG 0.00
- BOLD 0.00
- Stochastic Oscillator
- TRSG 0.00
- BOLD 0.00
About TRSG TUNGRAY TECHNOLOGIES INC
Tungray Technologies Inc is an engineer-to-order company that provides custom industrial manufacturing solutions to original equipment manufacturers in the semiconductor, printer, electronics, and home appliance industries. It predominantly generates revenue through the manufacture of custom industrial manufacturing solutions, direct drive and linear DC motors, and induction welding equipment. Geographically, the company generates a majority of its revenue from Singapore and the rest from China.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.